1. Market Research
  2. > Pathology
13 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • April 2020
  • 204 pages

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028 Summary Age-related macular degeneration (AMD) is an eye condition that is characterized by the gradual deterioration ...

  • Lymphoma
  • Pathology
  • Targeted Therapy
  • Therapy
  • Australasia

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2020

  • $ 2000
  • February 2020
  • 211 pages

The targeted subindications are mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

  • Leukemia
  • Lymphoma
  • Pathology
  • Therapy
  • Australasia

Heparanase - Pipeline Review, H1 2020

  • $ 3500
  • March 2020
  • 43 pages

Initially, it stimulates the DC, leading to the activation of natural killer (NK) cells that are capable of destroying lymphomas.

  • Lymphoma
  • Pathology
  • Therapy
  • Australasia
  • Progen Pharmaceuticals Limited

Australia In Vitro Diagnostics Market Outlook to 2025 - Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others.

  • $ 5995
  • April 2020
  • 503 pages

ASSOCIATE PROFESSOR WIEGMANS SAID THE STUDY COULD HAVE IMPLICATIONS FOR SEVERAL OTHER CANCERS WHERE DOXORUBICIN WAS USED, SUCH AS BLADDER, STOMACH, LUNG, OVARIAN, AND THYROID CANCERS AND SOME TYPES OF LEUKAEMIA AND HODGKIN S LYMPHOMA.

  • Lymphoma
  • Pathology
  • Australasia
  • Australia
  • Oceania

Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017

  • $ 2000
  • December 2017
  • 44 pages

Tumor volume reduction was seen in ##% of lymphoma case.

  • Digestive System Disorder
  • Lymphoma
  • Pathology
  • Australasia
  • Anthera Pharmaceuticals, Inc.

CSL Ltd (CSL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 95 pages

CSL Ltd (CSL) Pharmaceuticals & Healthcare - Deals and Alliances Profile Report Code: GDPH##D Published: November 2018 CSL Ltd (CSL) discovers, develops, manufactures, markets and distributes biopharmaceuticals and related products.

  • Lymphoma
  • Pathology
  • Pharmaceutical
  • Australasia
  • CSL Limited

Peter MacCallum Cancer Centre - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 28 pages

They are combining Dinaciclib with the anti-PD## therapy, Keytruda, in relapsed lymphoma, myeloma and chronic lymphocytic leukaemia.

  • Health Services
  • Lymphoma
  • Pathology
  • Specialty Hospital
  • Australasia

Diabetic Nephropathy - Pipeline Review, H1 2020

  • $ 2000
  • February 2020
  • 264 pages

Diabetic Nephropathy - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2020, provides an overview of the Diabetic ...

  • Pathology
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • Australasia

Diabetic Nephropathy - Pipeline Review, H2 2019

  • $ 2000
  • November 2019
  • 250 pages

Diabetic Nephropathy - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2019, provides an overview of the Diabetic ...

  • Pathology
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • Australasia

Australia In Vitro Diagnostics (IVD) Market Outlook to 2024 - Clinical Chemistry, Genetic Testing, Hematology, Histology and Cytology, Immuno Chemistry, Infectious Diagnostics and Microbiology Culture

  • $ 5995
  • December 2017
  • 544 pages

TRANSPLANTS ARE USED TO REPLACE DISEASED OR CANCEROUS BONE MARROW WITH HEALTHY BONE MARROW TO TREAT A RANGE OF DISEASES INCLUDING LEUKEMIA, LYMPHOMA AND IMMUNE DEFICIENCY DISORDERS.

  • In Vitro Diagnostic Reagent
  • Lymphoma
  • Pathology
  • Australasia
  • Australia

Hutchison MediPharma Ltd - Product Pipeline Review - 2016

  • $ 1500
  • December 2016
  • 49 pages

This study is in patients with relapsed and/ or refractory B-cell non-Hodgkin s lymphoma or chronic lymphocytic leukemia for whom there is no standard therapy.

  • Lymphoma
  • Pathology
  • Therapy
  • Australasia
  • Hutchison MediPharma Limited

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) – Pipeline Review, H2 2017

  • $ 3500
  • August 2017
  • 74 pages

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) – Pipeline Review, H2 2017 Summary Sphingosine ...

  • Autoimmune Disease
  • Lymphoma
  • Pathology
  • Therapy
  • Australasia

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

  • $ 3500
  • September 2016
  • 51 pages

The Phase II " DENALI" trial is expected to enroll approximately ## patients with first-line metastatic Stage IV non-squamous NSCLC whose tumors do not have an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation.

  • Hospital
  • Lung Cancer
  • Pathology
  • Australasia
  • OncoMed Pharmaceuticals, Inc.


View report >

Cancer Statistics

  • February 2020
  • 66 pages

Salivary gland Polycythaemia vera Oropharynx Other lymphomas Thymus Eye Nose, nasal cavities, middle ear and accessory sinuses Larynx Other endocrine glands Skin of anus (including perineum, perianal skin) Nasopharynx Malignancy of histiocytes and accessory lymphoid cells Unspecified sites

  • Cancer
  • Lymphoma
  • Pathology
  • Australasia
  • Demographic

Cancer Statistics June 2019

Cancer Statistics January 2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on